Bioartificial Liver

Scott Nyberg, S. A. Mao, J. M. Glorioso

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Acute Liver failure (ALF) is defined as sudden severe hepatic dysfunction in the setting of a previously healthy Liver. CLinical manifestations of ALF include encephalopathy, coagulopathy, hemodynamic instabiLity, and jaundice. Annual incidence of ALF in the United States is 2500 cases with acetaminophen toxicity representing the most common etiology at 56%. Although some cases of ALF remit spontaneously, mortaLity rates are as high as 60%. Emergency transplantation remains the only definitive treatment for patients; however, with Limited high-quaLity donor organs, alternative therapies including extracorporeal Liver support technologies are needed to serve as a bridge to return of native function or transplantation.Extracorporeal Liver support technologies include both artificial and bioartificial systems. Artificial systems remove toxins via filtration or absorption while bioartificial systems include biochemically active hepatocytes and are capable of performing synthetic functions including protein synthesis, ureagenesis, glucogenesis, and detoxification via the P450 system. A number of cLinical trials have been performed testing artificial and bioartificial Liver (BAL) devices with varying degrees of cLinical success. Widespread cLinical appLication of BAL devices are Limited by an abundant high-quaLity, readily available source of hepatocytes. Future directions for cell source include growth of human cells via in vivo animal models.

Original languageEnglish (US)
Title of host publicationPathobiology of Human Disease
Subtitle of host publicationA Dynamic Encyclopedia of Disease Mechanisms
PublisherElsevier Inc.
Pages1800-1808
Number of pages9
ISBN (Electronic)9780123864567
ISBN (Print)9780123864574
DOIs
StatePublished - Jan 1 2014

Fingerprint

Artificial Liver
Acute Liver Failure
Liver
Hepatocytes
Transplantation
Technology
Equipment and Supplies
Brain Diseases
Acetaminophen
Complementary Therapies
Jaundice
Emergencies
Animal Models
Hemodynamics
Tissue Donors
Clinical Trials
Mortality
Incidence
Growth
Proteins

Keywords

  • Acute Liver failure
  • Acute-on-chronic Liver failure
  • Ammonia detoxification
  • Artificial Liver
  • Bioartificial Liver
  • Extracorporeal albumin dialysis
  • FRG mice
  • Liver transplantation
  • Xenotransplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nyberg, S., Mao, S. A., & Glorioso, J. M. (2014). Bioartificial Liver. In Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (pp. 1800-1808). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-386456-7.04205-2

Bioartificial Liver. / Nyberg, Scott; Mao, S. A.; Glorioso, J. M.

Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc., 2014. p. 1800-1808.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nyberg, S, Mao, SA & Glorioso, JM 2014, Bioartificial Liver. in Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc., pp. 1800-1808. https://doi.org/10.1016/B978-0-12-386456-7.04205-2
Nyberg S, Mao SA, Glorioso JM. Bioartificial Liver. In Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc. 2014. p. 1800-1808 https://doi.org/10.1016/B978-0-12-386456-7.04205-2
Nyberg, Scott ; Mao, S. A. ; Glorioso, J. M. / Bioartificial Liver. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc., 2014. pp. 1800-1808
@inbook{073dd394f1424588a77c586baeb9313c,
title = "Bioartificial Liver",
abstract = "Acute Liver failure (ALF) is defined as sudden severe hepatic dysfunction in the setting of a previously healthy Liver. CLinical manifestations of ALF include encephalopathy, coagulopathy, hemodynamic instabiLity, and jaundice. Annual incidence of ALF in the United States is 2500 cases with acetaminophen toxicity representing the most common etiology at 56{\%}. Although some cases of ALF remit spontaneously, mortaLity rates are as high as 60{\%}. Emergency transplantation remains the only definitive treatment for patients; however, with Limited high-quaLity donor organs, alternative therapies including extracorporeal Liver support technologies are needed to serve as a bridge to return of native function or transplantation.Extracorporeal Liver support technologies include both artificial and bioartificial systems. Artificial systems remove toxins via filtration or absorption while bioartificial systems include biochemically active hepatocytes and are capable of performing synthetic functions including protein synthesis, ureagenesis, glucogenesis, and detoxification via the P450 system. A number of cLinical trials have been performed testing artificial and bioartificial Liver (BAL) devices with varying degrees of cLinical success. Widespread cLinical appLication of BAL devices are Limited by an abundant high-quaLity, readily available source of hepatocytes. Future directions for cell source include growth of human cells via in vivo animal models.",
keywords = "Acute Liver failure, Acute-on-chronic Liver failure, Ammonia detoxification, Artificial Liver, Bioartificial Liver, Extracorporeal albumin dialysis, FRG mice, Liver transplantation, Xenotransplantation",
author = "Scott Nyberg and Mao, {S. A.} and Glorioso, {J. M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-386456-7.04205-2",
language = "English (US)",
isbn = "9780123864574",
pages = "1800--1808",
booktitle = "Pathobiology of Human Disease",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Bioartificial Liver

AU - Nyberg, Scott

AU - Mao, S. A.

AU - Glorioso, J. M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Acute Liver failure (ALF) is defined as sudden severe hepatic dysfunction in the setting of a previously healthy Liver. CLinical manifestations of ALF include encephalopathy, coagulopathy, hemodynamic instabiLity, and jaundice. Annual incidence of ALF in the United States is 2500 cases with acetaminophen toxicity representing the most common etiology at 56%. Although some cases of ALF remit spontaneously, mortaLity rates are as high as 60%. Emergency transplantation remains the only definitive treatment for patients; however, with Limited high-quaLity donor organs, alternative therapies including extracorporeal Liver support technologies are needed to serve as a bridge to return of native function or transplantation.Extracorporeal Liver support technologies include both artificial and bioartificial systems. Artificial systems remove toxins via filtration or absorption while bioartificial systems include biochemically active hepatocytes and are capable of performing synthetic functions including protein synthesis, ureagenesis, glucogenesis, and detoxification via the P450 system. A number of cLinical trials have been performed testing artificial and bioartificial Liver (BAL) devices with varying degrees of cLinical success. Widespread cLinical appLication of BAL devices are Limited by an abundant high-quaLity, readily available source of hepatocytes. Future directions for cell source include growth of human cells via in vivo animal models.

AB - Acute Liver failure (ALF) is defined as sudden severe hepatic dysfunction in the setting of a previously healthy Liver. CLinical manifestations of ALF include encephalopathy, coagulopathy, hemodynamic instabiLity, and jaundice. Annual incidence of ALF in the United States is 2500 cases with acetaminophen toxicity representing the most common etiology at 56%. Although some cases of ALF remit spontaneously, mortaLity rates are as high as 60%. Emergency transplantation remains the only definitive treatment for patients; however, with Limited high-quaLity donor organs, alternative therapies including extracorporeal Liver support technologies are needed to serve as a bridge to return of native function or transplantation.Extracorporeal Liver support technologies include both artificial and bioartificial systems. Artificial systems remove toxins via filtration or absorption while bioartificial systems include biochemically active hepatocytes and are capable of performing synthetic functions including protein synthesis, ureagenesis, glucogenesis, and detoxification via the P450 system. A number of cLinical trials have been performed testing artificial and bioartificial Liver (BAL) devices with varying degrees of cLinical success. Widespread cLinical appLication of BAL devices are Limited by an abundant high-quaLity, readily available source of hepatocytes. Future directions for cell source include growth of human cells via in vivo animal models.

KW - Acute Liver failure

KW - Acute-on-chronic Liver failure

KW - Ammonia detoxification

KW - Artificial Liver

KW - Bioartificial Liver

KW - Extracorporeal albumin dialysis

KW - FRG mice

KW - Liver transplantation

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=85029060979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029060979&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-386456-7.04205-2

DO - 10.1016/B978-0-12-386456-7.04205-2

M3 - Chapter

AN - SCOPUS:85029060979

SN - 9780123864574

SP - 1800

EP - 1808

BT - Pathobiology of Human Disease

PB - Elsevier Inc.

ER -